AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02346487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/RTV pellets and AZT/3TC or ABC/3TC
Description: Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day
Study NCT03911271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: 0.01% atropine for 24 months
Study NCT03911271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Placebo for 24 months
Study NCT03389100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK6240 injection
Description: Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
Study NCT02506439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 mcg Vitamin D3
Description: Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Study NCT02506439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 mcg Vitamin D3
Description: Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
Study NCT02506439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
Study NCT04739345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
Study NCT04739345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline
Description: 400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat should be taken orally (PO) with food.
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given by intravenous (IV) injection.
Study NCT02952066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial biopsy
Description: Bronchial tissue taken during biopsy
Study NCT02438436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: simo decoction
Study NCT02438436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gum chewing
Study NCT01795469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoex compression garment
Description: 5-strap compression of abdomen, thighs and legs
Study NCT01376739 — intervention group
Intervention type: DRUG
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
Study NCT01868087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Boost Plus®
Study NCT01260311 — intervention group
Intervention type: DRUG
Intervention: Fesoterodine
Description: Any dose of Fesoterodine
Study NCT01868087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advanced Recovery®
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by intravenous (IV) injection.
Study NCT00722540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study NCT01073748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol
Description: single dose of paracetamol 15mg/kg.
Study NCT01073748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: single dose of paracetamol 15mg/kg.
Study NCT01873664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jaw-tapping
Description: to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
Study NCT01818557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood glucose testing
Description: Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
Study NCT00590083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL administration
Description: Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2.
Study NCT01946048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million.
Study NCT01724307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation of stellate ganglion
Description: An electrical nuerostimulation of the stellate ganglion up to 60 minutes
Study NCT00436215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg intravenous (IV) every two weeks
Study NCT00436215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
Study NCT01647880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum arm receiving Gilenya®
Study NCT01647880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator receiving Extavia®
Study NCT02704000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting program (Jamaica curriculum)
Description: Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
Study NCT02777190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
Study NCT02777190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
Study NCT00707304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin
Description: Oral, 1.5 grams twice per day
Study NCT00707304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice per day
Study NCT02708368 — intervention group
Intervention type: OTHER
Intervention: blood withdrawal
Description: 3 times
Study NCT02349477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gaba potentiating medication
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Study NCT01668927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT00687232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4818
Description: Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
Study NCT00687232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02169193 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-Rhenium Sulfide Nanocolloid
Description: 12 MBq of NanoCis added to 500 ml of enteral feeding
Study NCT02958189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tweet4Wellness
Description: A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
Study NCT02958189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: A Fitbit is provided to the group which tracks participants' daily steps.
Study NCT02958189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: A Fitbit is provided to the group which tracks participants' daily steps.
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
Study NCT02419755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
Study NCT01447056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP specific T cells
Description: Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection.
Study NCT02805088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalographic recordings
Study NCT02805088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Study NCT02805088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical evaluation of symptoms
Study NCT04048967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional development
Description: professional development of preschool staff
Study NCT03115801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
Study NCT03115801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Study NCT03115801 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation & immunotherapy
Description: Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
Study NCT03115801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
Study NCT00151411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
Study NCT00151411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00151411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
Study NCT00151411 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Intervention
Description: A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
Study NCT02033980 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NBI
Description: All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
Study NCT03508531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
Study NCT03508531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OSTAP block
Description: The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
Study NCT03508531 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT01696409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: 400 IU vitamin D3
Description: Take 400 IU once/day for 2 months
Study NCT01696409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: 2000 IU vitamin D3
Description: 2000 IU vitamin D3 once/day for 2 months
Study NCT03508531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT01048125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sympathetic Nerve Activity
Description: Resting Sympathetic Nerve Activity
Study NCT01048125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sympathetic Nerve Activity
Description: Resting Sympathetic Nerve Activity
Study NCT01048125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Stress Test (Color Word Test)
Description: A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure.
Study NCT01048125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Stress Test (Color Word Test)
Description: A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure.
Study NCT01048125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The Modified Oxford Technique for Baroreflex Sensitivity
Description: Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
Study NCT01048125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Modified Oxford Technique for Baroreflex Sensitivity
Description: Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
Study NCT01048125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Test
Description: The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
Study NCT01048125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test
Description: The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.